Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00779493 · ClinicalTrials.gov registry record · Phase 4
Curcumin (Tumeric) in the Treatment of Irritable Bowel Syndrome: A Randomized-Controlled Trial
A Phase 4 study, sponsored by Kaiser Permanente.
- Completed
- Registry status
- Phase 4
- Development phase
- 17
- Enrollment target
NCT00779493 is a Phase 4 study that has completed, run by Kaiser Permanente. The registered enrollment target is 17 participants.
The verdict
NCT00779493, a Phase 4 study, has completed, sponsored by Kaiser Permanente.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 17 participants
- Enrollment target
Study Summary
Evidence exists to support low-grade inflammation as the inciting factor leading to visceral hypersensitivity and alteration in motility in irritable bowel syndrome.In the medical literature,there is ample in vitro and in vivo evidence supporting turmeric and its derivative curcumin as an antitumor, anti-inflammatory and antioxidant agent. We propose a randomized, placebo-controlled, double blinded, parallel treatment study evaluating the effects of turmeric on the symptoms of irritable bowel syndrome.
Interventions
- DIETARY_SUPPLEMENT curcumin
- DIETARY_SUPPLEMENT placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2008-11 |
| Est. Completion | 2009-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00779493
The ClinicalTrials.gov registry entry for NCT00779493 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kaiser Permanente, which has 294 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which curcumin is the first listed.
NCT00779493 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00779493 about?
NCT00779493 is a clinical study titled "Curcumin (Tumeric) in the Treatment of Irritable Bowel Syndrome: A Randomized-Controlled Trial". Evidence exists to support low-grade inflammation as the inciting factor leading to visceral hypersensitivity and alteration in motility in irritable bowel syndrome.In the medical literature,there is ample in vitro and in vivo evidence supporting turmeric and its derivative curcumin as an antitumor,...
What is the current status of trial NCT00779493?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 17 participants. The study started on 2008-11. Estimated completion is 2009-06.
What interventions are being tested in trial NCT00779493?
The interventions under investigation include: curcumin (DIETARY_SUPPLEMENT), placebo (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00779493?
This trial is sponsored by Kaiser Permanente, which has 294 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.